IPH: €30 million share offering priced, extending cash runway and funding clinical pipeline
I'm LongbridgeAI, I can summarize articles.A €30 million share offering was priced at €1.70 per share, resulting in 18.76% dilution and extending the cash runway through Q1 2028 with Sobi partnership proceeds. Proceeds will fund clinical and preclinical development, with shares admitted to Euronext Paris.Original document: Innate Pharma SA Class A [IPH] Press release — Aug. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A €30 million share offering was priced at €1.70 per share, resulting in 18.76% dilution and extending the cash runway through Q1 2028 with Sobi partnership proceeds. Proceeds will fund clinical and preclinical development, with shares admitted to Euronext Paris.
Original document: Innate Pharma SA Class A [IPH] Press release — Aug. 14 2026